The US Food and Drug Administration (FDA) has given Novavax (NVAX) emergency use authorization to update its COVID-19 vaccine for patients 12 years and older.

Josh Lipton and Madison Mills monitor Novavax's upward stock reaction to this news.

For more expert insight and the latest market action, click here to watch this full episode of Market Domination.

This post was written by Luke Carberry Mogan.